Detalhe da pesquisa
1.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Lancet Oncol
; 16(8): 897-907, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26156651
2.
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Invest New Drugs
; 32(6): 1226-35, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25037863
3.
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
Cancer
; 119(16): 3043-51, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23775486
4.
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Clin Cancer Res
; 27(6): 1631-1640, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355200
5.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 6(5): 661-674, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271377
6.
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Lung Cancer
; 113: 51-58, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29110849
7.
Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Leuk Lymphoma
; 47(4): 657-63, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16690524
8.
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Lung Cancer
; 88(1): 63-9, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25682316
9.
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Cancer Discov
; 4(9): 1036-45, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25074459